ST香雪深陷多重危机

Company Dynamics - Guangzhou Xiangxue Pharmaceutical Co., Ltd. (stock code: ST Xiangxue, 300147.SZ) is currently facing multiple challenges, with litigation amounts exceeding 92.26 million yuan in the past year, accounting for 8.78% of its latest audited net assets [2] - Major lawsuits include a contract dispute with Guangzhou Wanbo Jiacheng Venture Capital Co., Ltd. involving 20.92 million yuan and a financial loan dispute with a bank amounting to 44.96 million yuan [2] - The impact of these lawsuits on the company's current and future profits remains uncertain as some cases are still under trial or unresolved [2] Financial Performance - Since 2016, the company's performance has been declining, with net profit dropping over 60% to 66.02 million yuan in that year [3] - The net profit has remained between 60 million and 70 million yuan in subsequent years, but a significant loss of 677 million yuan was recorded in 2021 [3] - Continuous losses are projected for 2022 to 2024, with losses of 530 million yuan, 389 million yuan, and 859 million yuan respectively [3] - In early 2025, the company initiated a pre-restructuring process due to its inability to fulfill legal obligations and a lack of debt repayment capacity [3] Restructuring Process - The Guangzhou Intermediate People's Court approved the company's pre-restructuring, initially set for three months, but it has faced two delays, extending the deadline to January 11, 2026 [3] - The pre-restructuring is a preliminary step before formal restructuring, and there is uncertainty regarding whether the company will enter the restructuring process [3] 2025 Financial Forecast - The company forecasts a net loss of between 635 million yuan and 934 million yuan for the entire year of 2025, with a non-recurring net profit loss estimated between 612 million yuan and 899 million yuan [4] - Contributing factors to this loss include intensified market competition, liquidity crisis leading to reduced revenue and gross margin, high financial costs, asset depreciation, impairment provisions, and extraordinary expenses [4] - Specific financial burdens include significant short-term and long-term borrowings with financial costs around 250 million yuan, fixed asset depreciation and amortization affecting approximately 200 million yuan, and expected asset impairments totaling about 130 million yuan [4]